Characterization of a putative cellular receptor for HIV-1 transmembrane glycoprotein using synthetic peptides
about
Pathogenesis of human immunodeficiency virus infectionProteomics computational analyses suggest that the carboxyl terminal glycoproteins of Bunyaviruses are class II viral fusion protein (beta-penetrenes)Peptide inhibitors of dengue virus and West Nile virus infectivityProteomics computational analyses suggest that the bornavirus glycoprotein is a class III viral fusion protein (γ penetrene)Human-immunodeficiency-virus transmembrane glycoprotein gp41 is an amino acceptor and donor substrate for transglutaminase in vitroA synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibitionThe phorbol ester phorbol myristate acetate inhibits human immunodeficiency virus type 1 envelope-mediated fusion by modulating an accessory component(s) in CD4-expressing cellsPeptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infectionStructural optimization and de novo design of dengue virus entry inhibitory peptidesMutations in the leucine zipper of the human immunodeficiency virus type 1 transmembrane glycoprotein affect fusion and infectivityReplication cycle of chikungunya: a re-emerging arbovirus.HIV-1 glycoprotein 41 ectodomain induces activation of the CD74 protein-mediated extracellular signal-regulated kinase/mitogen-activated protein kinase pathway to enhance viral infectionPeptide inhibition of human cytomegalovirus infectionProteinase-resistant factors in human erythrocyte membranes mediate CD4-dependent fusion with cells expressing human immunodeficiency virus type 1 envelope glycoproteinsIdentification of Peptide Inhibitors of Enveloped Viruses Using Support Vector Machine.Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 bindingFactors involved in entry of the human immunodeficiency virus type 1 into permissive cells: lack of evidence of a role for CD26.Calcium ions are required for cell fusion mediated by the CD4-human immunodeficiency virus type 1 envelope glycoprotein interactionThree-dimensional structure and antigenicity of transmembrane-protein peptides of the human immunodeficiency virus type 1. Effects of a neutralization-escape substitution.NMR and CD studies on the conformation of a synthetic peptide containing epitopes of the human immunodeficiency virus 1 transmembrane protein gp41.Resistance of primary isolates of human immunodeficiency virus type 1 to neutralization by soluble CD4 is not due to lower affinity with the viral envelope glycoprotein gp120Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein.HIV-1 envelope gp41 is a potent inhibitor of chemoattractant receptor expression and function in monocytes.The immunosuppressive domain of the transmembrane envelope protein gp41 of HIV-1 binds to human monocytes and B cells.Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope.Computational identification of self-inhibitory peptides from envelope proteins.Pseudopeptide TASP inhibitors of HIV entry bind specifically to a 95-kDa cell surface protein.
P2860
Q24634681-85F7B9B1-13DB-4368-A318-CBAC36ADF00BQ24800750-102F0DCE-F58B-44C7-A949-540D62486EC8Q24813811-2E1D69A0-5A60-4A43-9F85-1A5DBC4461D4Q27489799-A36C9485-BD58-4736-8C92-28EB8C612B63Q28298228-3A13ED7D-5008-42EF-B8ED-F1B4CE9A4014Q28317348-C3F5E03A-8FE6-44B6-9897-429207262E8EQ28368938-8D8D9753-AFE3-40BA-83CA-3A466925FCD7Q28369033-CF2F46BA-1052-4678-A2FF-D1561F7A3162Q28474595-DB433991-1661-4A08-9B88-74D3298D72ACQ28646740-0F7EFBA5-CCE2-4942-AC94-CEA00A181B15Q34042046-9DDF52C1-3AC2-4ADD-AA68-6BC098F9D3ECQ34062013-15E21DA8-DE59-4930-B2B4-BCD221CC0700Q34633529-92FAD428-7AC0-4E6F-91CF-83275ED494FAQ35832208-C816F511-FD99-464B-A1AD-D925535BD951Q35860797-7AC02CC0-86B5-4F1E-A404-2A0B7B4119F2Q36230268-350DD6F2-3A64-41BD-A484-28F939E2F7CBQ36636241-AE3D1E50-F0C5-476D-B0DF-C814C2275243Q36644356-55CA5C6C-CB67-4558-86F5-1A95D2B5BCF4Q36783109-40EB6CD5-DFB7-4D7C-82AC-5F5EAEF3042CQ36831177-97D0EAC5-A73B-4CC8-838E-2D9CC8F47588Q36833874-EB9C2AAD-C4BC-42CF-9CEC-A2F5DE6A0B3AQ36972346-FE21AC16-7C0C-42DC-BF3C-D1CA888DCB56Q37384536-B39D254C-DC5C-467C-BD09-53BE65A75644Q40120177-99F3631D-5411-4CFD-B4AC-33F7530404B5Q40265453-4FF6DA75-5872-4158-A049-64E4EBDD3345Q40288667-F47DF9B9-95C8-43F7-9900-F49A0367DCE3Q42550973-4EC9BCC7-7475-46F9-B383-84BA78229B06
P2860
Characterization of a putative cellular receptor for HIV-1 transmembrane glycoprotein using synthetic peptides
description
1990 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1990 թվականի հունիսին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 1990
@ast
im Juni 1990 veröffentlichter wissenschaftlicher Artikel
@de
scientific article (publication date: June 1990)
@en
vedecký článok (publikovaný 1990-06)
@sk
vědecký článek publikovaný v roce 1990
@cs
wetenschappelijk artikel (gepubliceerd in 1990-06)
@nl
наукова стаття, опублікована в червні 1990
@uk
مقالة علمية (نشرت في يونيو 1990)
@ar
name
Characterization of a putative ...... otein using synthetic peptides
@ast
Characterization of a putative ...... otein using synthetic peptides
@en
Characterization of a putative ...... otein using synthetic peptides
@nl
type
label
Characterization of a putative ...... otein using synthetic peptides
@ast
Characterization of a putative ...... otein using synthetic peptides
@en
Characterization of a putative ...... otein using synthetic peptides
@nl
prefLabel
Characterization of a putative ...... otein using synthetic peptides
@ast
Characterization of a putative ...... otein using synthetic peptides
@en
Characterization of a putative ...... otein using synthetic peptides
@nl
P2093
P1433
P1476
Characterization of a putative ...... otein using synthetic peptides
@en
P2093
L A Henderson
N M Qureshi
P356
10.1097/00002030-199006000-00009
P407
P577
1990-06-01T00:00:00Z